https://www.castoredc.com/blog/replication-crisis-medical-research/
In the past few years, there has been
a growing controversy surrounding the validity of a number of
cornerstone medical research papers. For example, Amgen, a US biotech
company, attempted to replicate 53 high-impact cancer research studies
and were reportedly able to replicate only six. Similarly, researchers from Bayer, a German pharmaceutical company, reported that they were only able to replicate 24 out of 67 studies.
Moreover, John Ioannidis, MD, Professor of Medicine and Statistics at
Stanford University—a strong voice in the replication debate—showed that of 45 of the most influential clinical studies, only 44% were successfully replicated.